Mumbai, July 26, 2017: Sun Pharmaceutical Industries and includes its subsidiaries or associate companies and Samsung Bio Logics announced a strategic long-term manufacturing agreement for Tildrakizumab. The agreement was entered into by Sun Pharma’s wholly-owned subsidiary and Samsung Bio Logics. According to the agreement, Sun Pharma has appointed Samsung Bio Logics to manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis. Filings for this novel investigational biologic has been accepted for review by the U.S. Food and Drug Administration (FDA) (May 2017) and the European Medicines Agency (EMA) (March 2017). The agreement was signed at Samsung Bio Logics’ headquarter in Incheon, South Korea. The approximate value of the contract will be USD 55.5 million, other financial details of the agreement are confidential. Commenting on the development,Dr. THKim,President and CEO of Samsung Bio Logics said,’Samsung Bio Logics is pleased to join hands with Sun Pharma and is looking forward to delivering best-in-class manufacturing services with global quality standards. Our collaboration with Sun Pharma is an important milestone for Samsung as it is a testament of our ability to provide reliable supply through its GMP-certified manufacturing facility to pharmaceutical companies, which aim to expand their global mark.’
United News Of India
